The hormone relaxin-2 is also considered an adipokine implicated in the protection against cardiometabolic diseases, being able to modulate inflammation, blood pressure and angiogenesis, induce vasodilatation, improve endothelial dysfunction during hypertension, and regulate fibrosis and ECM remodelling, two processes that predispose to hypertensive heart disease [146,147,148,149,150]. This evidence concerns the gene RLN2 and endothelial dysfunction.